Id|WorkbookTableauId|TableauWorkbookId|TableauId|Name
6670199D-BD81-4152-8022-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|8bca6479-2213-4ef4-aa1a-51f28abb98da|_Chart: Median Time to ART Start by gender
47DD8C98-C09B-4B94-802E-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|e4dbbc46-8ed4-46c7-824e-490cdffa1906|Ken Cohort
4574391C-17B2-42F6-809E-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|d1203d76-34a4-4724-a788-f3b20889083c|Proportion of Patients with CD4 at Enrollment (Overall)
58F5294E-4551-4544-80E8-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|1e5f9d98-8b11-4542-894b-832bd1c58f61|ART Cohort Population
31256025-2835-4B44-8167-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|ddbde5ba-56b1-4b70-850e-064d0c2adc5a|Number Of Patients (2004-2015)
6AC12388-2A1E-450B-8168-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|b15e10b1-0058-4961-9da5-17ecfce6af54|Number of Pregnant Women who died with 12 months by county
290B6F95-C0EE-4492-81E0-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|523c6f7c-c978-4cee-83d9-22a2c749ee9a|ART Adolescents
C15C4061-F9DF-4E5A-8211-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|8457316a-b89c-4e00-beab-f340c22dd185|Table:  Distribution of Initial CD4 count  by enryr of adult clients: National
D73DA2B7-5093-4310-822C-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|37439fc5-0a99-4fc2-b6bf-0d324039ab00|Proportion of patient records by EMR
728EDACF-6F7D-472F-8288-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|9db58f1a-d689-4e65-9982-531481d4b386|Table Number of Facilities
82168425-300F-40DC-829C-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|0b156ab0-e12c-4581-98ca-089f0549a1fe|ART Total Population Stripe
6DDD5AE9-9FB5-44BE-82C3-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|7cc1487c-550a-4885-b71f-95abba22d11f|All Under 5 Years stripe
393DBF21-645C-4FF5-843E-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|76fd8783-6327-4347-b66c-9604350b2ae0|Client Sex(proportions)
E65C0294-BD27-4212-8458-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|3a556f8e-a4ac-42ff-a87a-fb4619a5c119|Sheet 75
80852BDD-E950-4A6F-8475-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|74f8b7fd-f96e-4cc0-a8c5-06d1b90d0040|Table: Marital Status
AA706865-24C6-4728-849D-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|57beea3d-1f30-4b63-9ffc-69898a69de2f|(Marks)Time To Care (P50,P75,P95 by  Patient Source)
8CE248F1-4FC6-418E-84D0-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|8b550742-e513-4c59-b62e-170df930185b|Chart: Proportion Started on ART Patients Peads vs Adults
5E586996-A6DB-45A4-859E-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|c0df24f9-41aa-456f-bc86-92f4c5958b89|ART Children (5-14) stripe
5BE11E9F-9052-49C7-85E8-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|b6c1203a-b3e1-44ba-9ff6-4124180e6894|Table 2.2.5: Paeds initial CD4 % (0-4) 
26C3F316-E63B-487D-861F-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|e21aab09-b077-4ddd-88eb-e77841ecec2f|ART cohort age distribution
A6BD8537-9FA1-419F-864E-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|00698e0b-07ee-45dd-abf0-b48b3a88fc42|Table: Viral Load Uptake
B925C317-FBE3-4838-8739-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|e633db9d-70ad-458e-b235-97bc16e36673|_Pregnant ART Cohort Chart: Viral suppression among Active clients
47B89F55-2AD6-420F-8830-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|78b5c072-594b-47f3-b25a-62c9bb8298ad|12m,24m,36m,48m,60m retention Age Group
FE1059EB-A3DA-43E4-8877-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|7c2311e2-b0b0-451b-9322-b0b4813e10a6|Chart: Median CD4 count at enrolment by age / sex
69A8A5C0-C848-49DC-88E9-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|d52f3c35-20af-41a2-91a1-b8edc27d6010|_Distribution of Clients enrolled in 2014
9D8A7820-99B5-4D8F-88EC-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|8c996b41-f5d5-4959-8411-21476b7facc5|***Chart 12 month ART Outcomes for Pregnant Women at ART Start
3EE00741-3B69-4F4B-88F3-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|ba6dd24d-c227-4b11-8287-201aba323a7e|***Distribution of Pregnant women by Age Group at ART start
1EC045D2-749E-4520-88FD-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|be6b4861-3cfb-46ec-89b1-b5d2cf2c9f03|Table: Age at Enrollment (9,19,20+)
40CCFBCC-FA0C-45FE-8913-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|60e9c09a-338f-4e4d-a76e-830efe60758c|Chart: CD4 Count By Sex
E05E0BE9-182B-4EA5-89C0-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|a67bd446-d0c5-41ab-9bfd-988e3c234337|Adults
674D9A77-CA59-4B38-89D9-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|08caff28-aaee-4580-bbe7-9eac48277acd|All Adults Men (15 and Over) Stripe
CF4DA3DA-349A-4776-8A10-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|e3063b66-d422-4e46-86e9-46e2e55c7d67|Time To Care (P50,P75,P95 by Age)
8966E5AC-4E6E-4297-8A22-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|d71e25ba-54ae-44e3-a52d-1bc832dc10c5|Dashboard: Dr. Wamicwe
A59B1A99-DF12-4022-8A3E-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|a5b354ed-6da3-4685-95b7-f3571e296b76|_Chart: CD4 Distribution for all by Gender
400F3FF5-D3B5-4BA7-8A9B-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|a9955093-b3c0-4999-b2bf-6968956da7a4|_12MPreART_Outcomes Chart
51C578FB-9849-4D62-8AD4-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|4e19aa83-97ca-494c-9d3b-45f59ca4dbac|Sheet 144
BA23A128-404F-4219-8B41-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|b18c21f3-8166-480a-9e56-e6a8124a08df|Pre-ART Total Population Stripe
F6E73BC8-4310-484F-8C07-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|66b6763e-6652-4f3b-8d49-d13fa34b7f9e|Chart: Proportion of ART Patients by Age group at ART Initiation
489DE599-0462-46DC-8C8B-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|5606150b-e4c2-4502-835f-b8a91c32cacb|Chart: Median CD4 at ART Start over time
13E10862-1CFB-423E-8D0B-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|efdbd1aa-2a85-49ea-b5bc-b3a4fc37dde4|HMIS Statistics
558E0558-01A1-4FB8-8DA3-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|896ccc04-8c6a-4ed0-88e5-657712486d77|Dashboard 9
069932D0-3709-4564-8DA7-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|8b9f3df8-6a5e-47a4-acb3-5a3ca25ea80f|All Adolescents stripe
C9452D4C-4CC6-490C-8E34-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|9cbe6f11-ba2c-40c4-96a3-2080c48f911e|Number of sites intially uploaded
467AF5D6-0B1D-48BC-8E5E-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|5330219e-ed85-413c-a775-067c7f67129f|Pre-ART Adults (15 and Above) stripe
13066030-8242-4C9A-8F72-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|c730262c-5999-4f0f-a482-cf0ea8c8d76a|All Adult Females (15 and Over)
C8AF2485-76DC-4DFC-8FF3-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|8fd0a106-9326-4729-a996-ad3d38aeda7f|Time To Care (P50,P75,P90 children 0-14)
0AD05052-9A9A-4EBB-9050-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|106eaf81-259e-46ce-b1cb-f58144c5bf9f|Table: Number of  ART Patients By Age Group and Gender
6022B65D-7542-4480-909A-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|4331c882-b9e8-44b7-8f33-fb535cf989df|Valid / Invalid Time To Care Distribution 
556B9689-A54A-45A6-90C2-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|8f677b35-e752-4549-82fe-b7f68a85ea34|Chart: Time (days) to ART start by age group
086CB3B4-4ED6-47E9-9169-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|9e611aef-eeae-4b1b-a51e-46a35a33a3dc|Chart Median time (days) to ART start by year of enrollment. (Children vs Adults)
6EC6933A-6D82-42CA-9176-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|e508d7c5-04ba-470d-bcc0-86d73b46b64c|Chart: Proportion of  ART Patients Started on ART By Age Group and Gender
811852AF-3ED5-497E-91E7-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|23b7bc64-146f-49a7-902a-472d8023d911|Chart: Number of days to ART start Paeds vs Adults
700881AD-8D71-4DF1-9246-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|fb1037b5-fcfb-4b37-a13c-9ca7a1e0d30d|ART Cohort Dashboard
A88ED740-161C-4FB8-9275-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|f783f6bf-e370-4bc3-9ebb-5afd3ca30147|Number of sites with clean data
DA41B7B5-BF26-4D44-936F-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|642607b2-2b99-41fb-856a-b3c2402a27da|Chart: Number of clients eligible for viral load who have recieved viral load tests by year
FD7478E4-CEBA-4AEA-93D0-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|fc5cf6ea-6dd2-4ae8-9785-f0884b31d63f|Children
831EB419-32B8-46AF-93FD-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|e34cc157-cf1d-4274-ac5e-f48a89a8f32c|***12m,24m,36m,48m,60m retention Of Prgenant Women at ART Start by Regimen Line At Initiation
CCD0DEA4-D727-4A07-941C-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|a5ea6140-9173-442c-ae0a-a1d40c366864|Man
9BB39B58-9A94-4C03-94DB-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|a1d44eaf-f61f-4102-b3bb-94dbc3000b89|Chart: Proportion of  ART Patients Peads vs Adults
A3F57DA3-B1B2-4797-94F4-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|d0ceef12-56c7-4cf4-926a-12157fb451bf|_Table 2014 Cohort 12m retention by CD4 at ART Start
C6B61E51-CBA1-4549-951F-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|c8fde0af-9f4a-4b0f-9f4d-3a781935659b|Cohort Analysis Retention
9E0E3932-9923-4012-95A7-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|d6421a46-c39f-4a93-92f1-e4e9209db5fa|***6 month ART Outcomes for Pregnant Women at ART Start
D9F2C524-7C23-46F1-95BE-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|2c566e90-0d79-4ebb-9f87-713a56334289|Pre-Art Cohort distribution Age and Sex(proportions)
3C6B87D1-9A07-4097-964A-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|e8ab9415-ae96-4958-97f2-30b1bde072e2|Pre-ART Cohort Dashboard
1B7D73FA-6CF1-43DC-9694-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|3c07b67f-998e-49e1-a4b6-16cd9862c230|_Chart 2014 Cohort 12m retention by CD4 at ART Start
88A1B868-5F3B-4338-97F9-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|3a81e898-7767-42a4-a903-ab91ade84109|**12m,24m,36m,48m,60m retention pregnant women at ART start by Age Group
5661041D-13D7-4CB3-9887-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|63748264-4340-4725-a6c2-32496bd849e0|***12 month ART Outcomes for Pregnant Women at ART Start
767CEE38-0DBA-46CF-9887-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|50e07af9-5e4d-4c13-b054-8e3ff1dd2c4f|Table: 12mARTOutcomes By AgeGroup 
D85BD010-1460-49D7-98B0-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|9880ffab-7e42-4329-85ad-41023d3a110f|Pre-ART Under 5 Years
CD444897-6B03-4E8E-99AA-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|aa532bea-72a0-4e17-b45d-67876bc87f2e|Sheet 19
B69DA038-AEB8-498C-99BF-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|bcd715fe-38fb-4b00-9eb2-4d4bec129748|Proportion of Patients with baseline CD4 at initiation (ART)
63587180-8322-4859-9A2A-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|b9237ca4-7397-48f3-ae0e-05bba49bfa2d|Median by Year of Enrollment
ED579597-C877-4EA4-9AAA-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|b716b61c-f0ea-4788-a940-c090d4f80961|Table 2.2.4. Availability of paediatric Initial CD4 count  stratified by age: National
ABF9E8C6-E0BC-4D13-9BF4-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|8718b1f5-d5cf-4956-a4cf-c8afe6f2eb41|***Initial ART Regimen distribution among pregnant women at ART start
5CA223E8-972F-424C-9BF5-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|97ad9a0f-ac14-4074-81dd-73961208626a|ART Under 5
8EE9272F-CF0F-4FC8-9C56-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|5fe67e0b-2da2-43fa-972e-a47ed60c6a62|__Chart 2014 Cohort 12 month ART Outcomes by Baseline CD4
CD1A635F-ADFE-47C1-9C71-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|1c2d716b-ed5b-4983-9701-1a494ffbb039|_Chart: 6 month Pre-ART outcomes
2C6AA1F9-61F7-4F43-9D32-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|f695a297-0097-4388-9288-c081f5a8962a|Table: Has Enrollment C4 (15+ Yrs)
AF95E52B-B908-4990-9E2E-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|f23de195-e4f8-43c0-a871-d123d81525f6|___ART Cohort 12m retention by Age Group
0D6A968F-CC79-46AC-9E2E-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|b6d2cba7-a65e-4339-9add-657e59c0d46b|Table: Age at Enrollment (0-65yr)
01D500A3-69A1-4EFF-9EE8-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|7a18fb0c-4e09-4dd6-a451-07dcfa17d9f6|Table: Proportion of Children <5yrs with CD4 Percent at Enrollment
381D5FA4-995E-46BF-9F5B-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|fcb7ebcf-17ca-4391-a74a-351f893f70ed|Kenya map
CB4F2C68-67BF-462D-9FA3-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|2c9830c3-045c-4a04-89fa-b3f5ee66857f|(Proportion) Time to linkage  (Late vs Early linkage) 
93AA9D49-BF8E-4056-9FC6-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|af3b18a2-cb93-4b19-83b8-e883f511771f|Chart Enrollment CD4 Distribution by year of enrollment
68DB3F59-0E6C-4E96-9FDC-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|7be0d5e2-cdf6-4ed5-a747-a698cd5d9ea5|ART Adults (15 and Above) stripe
B4D0A652-1686-48E8-9FE8-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|a1b0c619-dfa0-443a-84db-4cbe2a31df3e|Pre-ART Adolescents stripe
EEBD8D90-8F76-4114-A023-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|397bac0f-8059-4543-9bb6-29c03efb56c0|Chart:  Distribution of Initial CD4 count  by enryr of adult clients: National
695F018C-0B89-4C58-A033-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|a157a4e9-1880-4f43-8ba5-cc9784e0b45b|Table: CD4 Distribution for all by gender
313C97CC-ABBC-4B4D-A058-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|fdb0be08-6988-4850-86ba-d5c7da8a8b2f|_12 Month Pre-ART outcomes
536B2281-3E84-4E5E-A06E-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|152fb736-80f8-4fd2-b5a9-f4a16414ead2|Distribution of Patients in DWH Dashboard
39883909-059B-4793-A0D4-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|098985fe-1f24-40eb-93ab-ed59991710c7|_Chart: Marital Status
093C34B5-0617-48B8-A1B6-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|3e02f246-13a9-486a-b92f-66c153bf1a1d|***Retention pregnant women at ART start by BaselineCD4
A435D46A-FA9D-4238-A1DE-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|c00db352-2314-42ea-820a-534472f7c42a|Table: Number of  ART Patients Started on ART By Age Group and Gender
E24C6D0D-D6FC-409E-A2A9-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|6f29d868-a50d-49d1-92e8-8db18dfff89f|_Chart: Median CD4 at enrolment by year of enrolment and sex of adult clients: National
7E7030A2-A5CA-4243-A340-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|49575543-3b27-4503-8848-752ee49432f1|Table Enrollment CD4 distribution by Age at enrollment (Adolescents vs Adults)
634EF9F0-77F1-41FF-A384-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|1e549c1a-8017-4257-9af7-72097be7da4d|Number of Patient Records
53A4AAF3-EDAF-4044-A39D-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|40dad4c7-f34b-4017-85db-0b42f21a769d|Woman
4888FB2E-9303-45AA-A4D5-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|51376901-8aa6-44e5-a4bb-f3c7035c2748|Chart: Yearly proportion started on ART Patients (Peads vs Adults)
40D2F1B2-0D85-4391-A4DC-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|8feb49c3-9adf-4b65-afdf-b1b8c3398e38|Table: Number of  ART Patients Peads vs Adults
BBFB702A-6525-41D6-A4E5-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|b40f5d42-a191-4e72-bf10-c5a4aaab9d47|Table:Age at Enrollment (14,15+)
3C60DA60-A476-4A44-A555-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|a480d54f-6aae-490a-a031-06ea0eb0bbac|**Median time to ART Start among pregnant women at ART start by Age Group
314D335B-B30C-46D7-A5C5-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|144d2eee-03e1-4b65-9ac4-cc6b071eaf58|(Numbers)Time to linkage  (Late vs Early linkage) 
5D171123-D977-4800-A716-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|7fbe1c19-b79c-4e7a-b9ac-23194f011da0|All Children 0-14 Stripe
3360B267-BF62-47C6-A72D-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|c0f9a3e4-6a32-4b0d-bab4-bb5b74825751|Number of Patients by Age at enrollment by Year 2004 - 2014
04C2A47A-3726-43EB-A73A-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|4782c360-a09f-4e7c-ab07-a91ed5df560d|Population
D0BA72CC-FD3F-4F24-A77F-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|b261902c-76b0-42fd-86ed-745532d83165|Table: Outcomes by County
602EFBDA-8C63-4C7A-A7E5-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|7820adc5-bfbf-4bed-a3b0-9523aeb33b88|Chart: ART Patients Marital Status
B25BE4F8-A8F9-43C1-A8F6-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|f0f902a6-db62-4bf7-87b2-499200ec04df|All Adults (15 and Above) stripe
0FB8B633-BDE9-4564-A918-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|4c037d62-ca69-4fa2-973f-5b0ae5ec0725|Pregnant Women Dashboard
24D32C9A-D0B7-4450-A970-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|e65d2808-d543-451f-a4ce-b3b4571dffd1|Pre-Art Clients Alive and Care at end of 12 months
D2ADFFD6-B024-4EF3-A988-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|0f98ada8-d398-4e99-a886-00a5c05b8a73|Table: Time (days) to ART start by age group
73847404-32C9-49FA-A9B8-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|376df9c7-a81e-4d0b-9713-d6ed14498586|Client Age and Sex distribution
63422A06-F004-461D-AA1D-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|aa16fcb8-5d7c-4eaf-8a57-8727a2b56ff5|***12m,24m,36m,48m,60m retention pregnant women at ART start by Age Group By County
6153FACF-7DE1-4640-AA28-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|363a283a-d5ed-47d2-b2d9-62f5bbc38617|Total Population Stripe
35705F91-1ED1-4893-AB0F-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|ffd13f60-4893-4064-8e69-a706307db06f|Dashboard 3
4FA486BD-0089-4031-AB53-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|0fb9c049-c31e-4f99-8aa5-d6e050d22868|Table: Number of ART Patients with baseline CD4 Adults vs Children
118D669C-2859-4794-AB54-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|1ead2898-009c-46e5-b0d6-a5704fa1743a|Chart median time (days) to ART start by year of enrollment
350C63C9-998F-4B5F-ABB6-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|790245c5-7d80-4ceb-9d88-66a9b2965be2|Proportion of Patients with Baseline CD4 By Age Group
BA5A5452-F4C7-4087-AC51-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|f141c58b-0de2-4dde-81a0-0e8fe773762a|Chart: CD4 Distribution for all by Gender
5E95042A-8BD3-4352-AC6B-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|cedf2367-a79e-4bd9-8bf6-3bfce66ef94b|Chart: Proportion of ART Patients by Age Group and Gender at ART Initiation
6009E13B-F190-4CB5-ACE9-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|76cf54c6-a977-4759-840b-316f571b231b|***12m,24m,36m,48m,60m retention pregnant women at ART start by Age Group by Project
F5A0B11A-49F7-492A-AD23-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|52d6074c-9cd5-40c9-977b-7193bf8c2af4|Pregnant ART Adults (15 and Above) stripe
123FD37A-D28F-4CBB-AD51-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|dd776f47-95a0-4d5f-8508-2a6228ecdd45|****12m retention Of Prgenant Women at ART Start by Age group 
BCEC8F34-B8A1-4E19-AD8B-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|42257b1e-cc3e-467d-b209-7127b8ad7057|Number of care and treatment sites
398898E3-6258-471A-ADF3-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|30af8917-aade-4a9a-b434-2e9460a16941|Table: Number of Patients with Baseline CD4
41130C37-2F69-4932-AE6F-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|adaf2428-5718-4fa9-b9bc-c2f5eeff1244|Pre-ART cohort age distribution
03D49814-D7F2-4882-AEB2-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|1a622d02-e753-4775-b365-53d934f8070f|Number Of Patients By Age Group
FF244288-6A8E-408C-AECF-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|bb33b092-8e34-448a-b9ab-936932b63ec3|Table: Median CD4 at enrolment by year of enrolment and sex of adult clients: National
1E3B10CB-A228-45AE-AEEE-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|5208e875-8d97-4e90-870c-4bb7a87ab0ea|All Children (5-14) stripe
06626972-137D-409E-AF85-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|c03ed8e7-1b1a-497a-a770-b584836961d4|_ART Cohort Chart: Viral suppression among Active clients.
6D0BAFD9-70A7-4774-AFDA-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|897f5562-b974-4040-88ea-638efcc1e102|ART cohort sex proportions
939956A5-EAEB-4A33-AFE2-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|ed5b9578-5e17-4dac-8716-81b8e024115f|Pre-ART Children (5-14) stripe
E6CE437B-31D4-4AF1-AFE2-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|8e91ae2a-dc19-4e5c-a679-2cef4c323ba8|_Chart: Overall Time To ART
B529856D-5BF7-43C4-B134-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|e9ff675c-e034-4216-961f-14f6eaf34187|Chart: Age at Enrollment (0-65yr)
E3E698D7-C847-4DDA-B29A-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|ea7f1a62-5870-46b7-baee-bd5216875b93|Baseline CD4 by Age Group for Pregnant Women who died within 12 months
40B12402-85F3-4EF9-B31F-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|47eee886-5ca1-4511-8209-0ae379bc9063|***Last ART Regimen distribution among pregnant women at ART start
112FB11E-2ADD-48A7-B415-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|9dfaedd2-b3f1-40ee-811d-7466cd89664a|Table: CD4 Count by Sex
380ABE1F-609A-4F6F-B450-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|1e420625-b47f-4e30-b0cb-0f5677dc282b|Time To Care
8C5010A8-0EA2-4056-B501-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|fae63746-6be6-4794-9340-6eda464e8e27|****Chart: Median time to ART Start among pregnant women at ART start by Age Group
B43BF2D8-ABD0-497C-B546-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|8fcb991e-8a5a-4e5d-92bf-6f9b8cd1a743|(line) Time To Care (P50,P75,P95 by  Patient Source)
F272725E-BE87-45E8-B559-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|e26cb216-1dad-4c4f-9b63-75bd12910e4d|12m,24m,36m,48m,60m retention by CD4 at ART Start
D3876501-11C8-4B21-B581-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|445d78a6-1b0e-4de4-be60-9458498b0bb4|Sheet 16
040D02A1-6610-436D-B65F-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|370380e1-8465-46ec-9984-9d52916231b1|_6MPreARTOutcomes
363413E0-C80E-4214-B669-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|c9b2f98f-ce20-4736-906f-6ccb1299dc6b|Chart: Number of Started on ART Patients Peads vs Adults
D62D787E-7807-48E5-B6DF-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|54d64ef7-3288-4d32-8cf3-15ee8b4085a1|Pregnant ART Adolescents
2F87D66C-8A42-467A-B911-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|0ca6a070-5296-4529-b5aa-f4296fa60f90|_Chart: TimeTo ART Start groups
CA7E3029-B761-408C-B983-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|b1780c58-95d1-46b6-b9c5-7a50acc77087|Chart CD4 Distribution by Age (Adults Vs Paeds)
049D5338-AA5B-4226-BA87-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|5145fa30-59e5-46c1-8645-9279c1cf1872|ART Children 0-14 Stripe
C14B4860-548E-4EBA-BAD8-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|d7230edb-04f4-4a1f-8498-825b65eb77c7|Chart 2.2.5: Paeds initial CD4 % (0-4) 
E0E1C09D-0997-4EE0-BAF2-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|ba0becf5-b17f-401f-8899-56f424570de6|_Chart: Median Time to Art Start
0F2EE3F4-61BA-47E4-BB07-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|5f34a6f4-7d13-417a-8a45-d00b8ba21d91|Time To Care (P50,P75,P95 by Sex)
C0A75D57-2D23-47D4-BB0A-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|a2447f0a-032b-44b0-a6a0-cd87216eb70d|***2014 Cohort 12 month ART Outcomes for Pregnant Women at ART Start by Agroup
36614261-95E7-40E2-BB73-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|a1084cd8-0725-42fa-bd92-d2267e371d29|__Chart 2014 Cohort 12 month ART Outcomes
FF142369-CF2E-4DB8-BBA6-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|1f27839f-2d9f-4930-baf4-4c031f5258fa|Enrollment Numbers by Age
0A2698FA-3EBF-4FE1-BC52-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|46f2d999-d544-4c8b-91b1-5a9dd6d432bc|ART Cohort Age Distribution
E5B16140-76AA-4DF2-BDF4-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|ef0129a3-f661-4a21-b9ab-d57e7763a876|**Median time(days) to ART Start among pregnant women by year 
1B3E8C43-D656-47C6-BE15-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|53dea344-c975-4580-8f66-81bbd0d8e327|Chart: Proportion of ART Patients with baseline CD4 Adults vs Children
5108FCC0-B4D8-466C-BEB4-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|d8e534f2-cce8-4c43-a112-d39c6dd8b05f|***6month ART Outcomes among pregnant
AE53FF49-E94B-4223-BEBA-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|2cda1e8c-0347-48c5-bfad-7b6feff5bb99|Table: Median CD4 count at enrolment by age / sex
6DACFAD0-1566-4DBB-BEF6-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|77594e73-2ca5-4b28-aa71-4b8417ae4aaf|***2014 Cohort 6 month ART Outcomes for Pregnant Women at ART Start by Agroup
A9FDDB22-8D8A-4689-BF6B-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|b925e6ed-f5e8-4ef2-96e8-1b3cbcea6d81|Sheet 154
2FFD3ABE-84E9-4054-BF8F-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|ad629367-c373-486b-81f8-e545df8b9b75|_12m,24m,36m,48m,60m retention by Year of ART Start 
A14A5DF4-3EAA-42EB-BFFA-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|7f475d96-8fe7-468c-bce0-233de795b408|Chart: Median CD4 at Enrollment over time
40D045C1-8DD3-4F31-BFFC-A7A1012EFB71|f984429a-7706-4677-a616-972cff17d388|E3F030FA-1BF2-4497-B8CC-A7A1012EFABD|26096372-f4e4-460f-a985-5d13c9643596|Pre-ART Children 0-14 Stripe
86FC0681-0F49-4D8E-9D58-A7A1012EFC0F|8de742c7-8038-4f6d-8b56-ec0e5b22b9fc|95EC1986-EBA9-429F-A9D4-A7A1012EFABD|b334f5ce-def7-4d55-a6a3-3b685a119d05|Implementation_Dashboard: PLHIV EMR Coverage
DFD3EC0C-91B0-45AA-803E-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|bfd71825-147c-40ae-b96d-bc122b4c06c3|Implementation Dashboard: Facility Profile
531C557D-EFFA-4F4B-81FC-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|ab432625-fdb7-46cb-a27f-c8e6e48950c2|Number of Facilities
27EB2462-01AA-45B7-82AD-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|7998bbb8-9692-4a1b-9926-00c69463d1d0|Table EMR Buy in
287DA057-F2D6-4ABA-82D8-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|eb92d5ff-cbf7-47b6-8a22-10938d820bb1|Map: Implementation by EMR
8B96A354-D764-4982-8404-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|f1f6c07a-d72b-45fc-aeec-ebd1a087eb13|Implementation_Dashboard: Org Unit Profiles 2
AECE4D43-42CC-442E-84A1-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|d4ca24b3-f509-4080-9e44-1b741639f5dd|Chart: EMRs Workforce and appointment Management
38406809-1FFF-45FF-84ED-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|b0ff5b92-8240-49c2-9787-b3bd98f15f6c|Map: Facility Distribution
4B2CA901-50E8-4F86-8550-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|907143fb-dfa8-4663-a172-6fb5ae634791|Chart: EMRs Generating MoH 731 Report
32439C06-1C46-48A6-85D1-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|c8fc2d81-63c5-4ace-906b-12878091d50c|Terminals Supplied for LIS
D9A60850-8BA0-4C12-87A6-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|7b1e8ab5-6c58-4130-b7a7-8f82e7c32021|Table: EMR Data Use
43A17722-E785-454E-884E-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|9cd554a3-40c7-464b-943a-46b4f9244855|Table: Table: Computer Terminals Supplied for EMR
304DFF9F-B454-4837-88B5-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|0b833b96-e008-40cc-93a2-58ec9ec2db9b|Pie: Sites by Mode of Use - May 2017
0039BFF7-D75D-4C81-88DE-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|83e26848-1c8b-4dcf-813b-12bd0f7ff1a9|Chart: Sites with  functional power backup systems
66DE274A-20CD-44E5-8984-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|c800748f-9265-4414-ae42-d63a466c8812|Chart: Sites generating MoH 731
FB176D33-FF75-4FD3-8A68-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|9bcaabf3-1de8-4e22-8b55-04ed57e74e33|Number of EMR Sites
B4272381-4B7D-42F2-8AB0-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|ea6c212f-2cfe-4121-b520-db1ab892b728|Chart: EMRs Facilitating clinical decision support
70D063CD-DA41-41F8-8B67-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|7996c6c6-f5b9-4c50-b50a-92da5c78d267|Story 2
75C911CA-3EAE-4A2A-8DE8-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|45b6af83-e26f-479f-82f4-4973683be5e0|Pie: EMR by Type of EMR
21AA4172-DA02-4B64-8F6D-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|c29d5039-cec4-47e7-8a01-f71ba468b535|Pie: Sites by Mode of Use- Dec 2016
AA5B26B7-9672-4B7F-8FA2-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|794d348b-ec69-4963-a44c-9b72b167b62f|Table: Facilities Supported by USG Agency
5AEFF76E-E766-4EB0-90C2-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|c3f1310d-4675-4619-bcd6-df8c29a042c1|Implementation_Dashboard: Implementation by EMR
4B3E5354-B613-4FFF-92A5-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|73ee2f8a-0cc5-4d49-a98f-e09d2b9fb722|Mode of Implementation Number of Facilities
CECD58B0-0738-4D66-9394-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|bb5cbc54-26b2-426f-a502-fe55989373d5|Chart: Average Level of Legacy Data migration by Partner
58236DC6-B9FC-45FB-949E-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|71218bd8-5bf3-40ac-91ca-6fe2840145b4|Table: Number of Trained Users
14D7A16D-7D05-49A3-94FE-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|80d994ea-2334-4a97-92ef-35c9b0fb91a3|Chart:  Active Status- May 2017
CC6CBE3F-BF6C-4940-9523-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|8f3e9220-586b-4f21-b597-d593eed227e3|MFL Number of ART Sites
0FC3B276-9CA9-4791-9618-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|48ad20ee-ebcc-43df-97dd-450e6eab7318|Table: Number of Active Patients vs Ever Enrolled by USG Supporting Agency
BAD83B41-1421-4BD7-96B8-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|5ea20b3f-dd00-441c-a61a-ca90e3f58b68|EMR Implementation Mode
C6E690B3-9D4A-4F4B-9710-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|89d18acd-2c0e-4194-a487-9746e018f8d9|Map: Facility profile map
EB441905-489B-4912-9791-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|12fb6b1b-c5b9-41ba-8dd3-411bba0b509d|Facility Infrastructure
059CAAE4-980F-4F5E-9B8F-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|121d0e54-9e12-46dc-963e-b7fe6ec5479f|Table: Proportion of Sites by Status, Agency and CT
FAC13924-F637-4D7B-9D21-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|7c9b87f3-dcd6-427a-a27d-0a8ffe6ef559|Map: Implementation Mode Of Use
E364E998-BDB6-47E6-9E4E-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|9d79648f-5a7d-43c1-934a-3448252bb63c|Chart: Sites Active Status- Dec 2016
AAE4EAA2-16D3-42C6-9E99-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|c71f11d8-d74f-4b57-bb93-9b463fc94a4e|Sheet 48
03103FE4-96DE-474F-A0D5-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|6b2fd877-30d6-46db-958b-0d991dcef4fa|Sheet 42
2A4E2418-D0CE-43B3-A0F9-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|79320799-20ef-4a82-9f23-9638a715d200|Emr Use
AD476318-A437-472B-A183-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|ae2efdc4-d294-49ac-bc8c-b7ef9c64256c|Table: Number of Active Patients vs Ever Enrolled
7D17BAB0-ABDC-4AFA-A4C7-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|8cab9a2f-1d29-4146-b090-6fdf04a0cee6|MAP: County Implementation Map
9A72A226-F904-4E79-A53B-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|e510c445-13e6-4d8c-a87d-7f3dd9d41e79|Chart: EMRs generating Adhoc Reports
26DC7C8E-9EBD-436F-A596-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|65ea079f-fb77-40b7-98e8-d4e7eae09e95|Map: Status Of Implemetation
03F80122-0386-4C10-ADE1-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|35924995-936e-4b25-bac4-b8a8ce2a085f|Sheet 43
A433918F-C953-4C52-AE10-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|7ecf2300-c516-4ff3-918a-1eb400fe0a8d|Implementation_Dashboard: Facilities by Implementation Mode
3CF2D5AB-4588-4DE4-AE6A-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|dc51a715-3f97-48c4-8243-9ff826420100|Chart: Sites generating Ad Hoc Reports
24D16E2E-2740-4B81-AF80-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|23340077-d4c9-4400-971b-04112eff0d20|Sheet 17
B3B3B369-F674-40A1-AF8B-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|2cb6a6dc-7a73-48e2-a639-462e5e34e6ee|Map: Facilities Supported by USG Agency
177B900D-DDFB-4E48-B263-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|1463bbcb-c3de-4f48-bc49-07390feefcb2|Chart: Sites with  functional backup device
2112A458-48AA-4434-B29C-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|bf74747e-7863-4f5f-aedc-a177fd89051b|Chart: EMRs Supporting clinical workflow across treatment cascade
6558B4B9-5670-42D3-B2AA-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|4d6f983d-605e-42dc-91d7-e69833cd3d41|EMR Implemntation
CA84D1A6-0294-4929-B2AB-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|08d2745d-7947-486e-a404-450a4441eebd|Dashboard: Implementation Statistics
42A2A686-355B-4C05-B3AE-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|c97ac4c2-03ef-4b21-9384-dc789a880f5c|Facility Workload
8763DCF1-DE48-4ECE-B627-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|62056a80-b9ad-41b7-a091-ba8745c4b2ae|Chart: Sites with EMR Committes
69AE4253-867E-4449-B66D-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|05c2b154-4f36-4b24-8c93-98f51df20e68|# Implementation by EMR
9545C644-2E9B-43CC-B7F6-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|52cb475f-39e1-4a3b-91ef-64719a28d737|Pie: Implementation Status
7C697635-99F3-4CD6-B873-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|8710b107-0a89-4bd6-9e9c-1dbf98295a79|Implementation_Dashboard: Org Unit Profiles 3
CA3AF286-B125-473D-B974-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|ccf388b0-7c00-47b0-8467-83ed12f33cfd|Table: Sites by Mode Of Use- May 2017
910DCD1D-3968-483C-BC1B-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|ee347bc1-96d0-46a9-aae3-5464689ff3f5|Pie: Sites By Category-May 2017
4FA8435C-A2C6-4B0E-BF38-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|02575bb4-c92c-4010-8264-adff420d65df|Implementation_Dashboard: Org unit Profiles 1
C7FBE22D-B137-4E50-BFA9-A7A1012EFCA7|487a077a-4264-4e24-9f6d-43d8a70b0d31|351A8B71-8510-420B-80CE-A7A1012EFABD|b94a540f-ff21-4426-af3c-820660d24707|Sheet 24
E9393902-0846-44EC-803B-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|8abdc69f-580b-4666-b9ef-0775caa42f9b|Strip: Number of care and treatment sites
6AD361E0-5311-4029-8052-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|3d271fd1-e14f-43cf-ad01-ce7352852cd6|Live Dashboard: HMIS Statistics
561DE4CD-A8C5-459E-806F-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|856e941f-4676-4aa1-af4d-92ca040c2f28|Chart: Median time to ART Start among pregnant women at ART start by Age Group
3BDD46FE-EF34-45E0-80A7-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|5e297eb6-42e0-418f-9d3d-a8fa5f649c41|Stripe: All Under 5 Years
FC2F8B53-62C1-484E-80BC-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|495c3e70-16e9-44b6-9af5-352be168a18f|Cohort_Dashboard: Pregnant Women 
AAE668BB-D589-4776-80D3-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|7a1a2e18-200a-43b3-a325-6f84d746ec91|Table: Client Regimen line
6BBB4630-1331-44C2-80D9-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|f8e47414-5e5a-41fb-ad92-91ce1a083953|Chart: Sites Missing Visit Information
60FC688B-DCAC-41EC-80E9-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|636cf601-9240-44f5-9ad6-2c983d7fd1f4|Chart: ART Patients Marital Status
A84EC29C-558E-49E5-816E-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|775cef53-7d96-47ce-8444-667fe35a9d2f|Stripe: ART Adult Males (15+)
155F5869-318B-46A6-8177-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|3cedb4fc-3deb-4283-a403-73d066d297bf|Chart Enrollment CD4 Distribution by year of enrollment
B73ED652-D143-473D-81AF-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|b1cf5c39-7d88-4515-a34e-252fcc70c491|Table: Proportion of Children <5yrs with CD4 Percent at Enrollment
0D5FD154-8EDF-4E2C-8226-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|00107778-c904-4613-acb9-daeebe0be4d2|Table: Cohort 12m retention by CD4 at ART Start
EA7F4125-E76C-4B76-82A7-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|1980ab12-84b3-4b41-99ce-393594053c82|Chart: 12m,24m,36m,48m,60m retention by Year of ART Start 
B46C2609-C478-4A2B-82B1-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|dff2a954-26c7-473c-a95f-c5c0165060ea|Chart: Proportion of Patients By Age and Sex at Enrollment
C084FB25-A41D-47C4-8335-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|fafc217d-a549-4fdc-897f-d4540fc07198|Table: Has Enrollment C4 (15+ Yrs)
C13A3FFC-8273-463F-83B7-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|01033519-f056-4b22-adb5-445ee3876c25|Chart: Proportion of ART Patients with baseline CD4 Adults vs Children
1DABDFC3-90A9-47CF-8500-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|b4b0dd75-ea0d-44e4-bae3-811b761d10de|Chart: Viral Suppression among Active Clients
32A964D8-26E9-466C-8511-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|ff062e85-bd1e-40b4-b87d-a6870ff2ba3a|Sheet 194
8401CA49-95CE-4520-856A-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|6bda366c-bb2f-40a0-a358-b3364cd5a2e7|_12 Month Pre-ART outcomes
0F152684-3CD0-4AB0-85A7-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|f5f63e52-296e-43d4-addf-12ce508590ff|Chart: Proportion of ART Patients by Age Group and Gender at ART Initiation
79299D01-29C2-4956-85F7-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|469426c8-b7f5-44ca-b946-b371b899efe3|Live Dashboard: Retention by project
D756744A-B9CD-4DAE-8637-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|0a216be7-559e-40a3-ab1f-1ce37b75a029|Chart CD4 Distribution by Age (Adults Vs Paeds)
30BAA687-79F9-4A33-8649-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|89633d7e-bf01-4871-a43d-f109fccb36af|Table: Number of ART Patients with baseline CD4 Adults vs Children
B70129F0-E85C-4783-86EF-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|b4d831a0-8eb5-4267-87b1-8b9bf1c4f968|Stripe: Stripe: Pre-ART Adults (15 and Above)
BACD0850-EC4B-4044-8709-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|4620e7d8-75c2-4cad-9d77-950dda0920d2|Chart: Retention by ART Start Month
045DC0D7-9A9E-4AEA-870E-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|5b7f94f6-99b0-4580-b1b6-a7ff43f45e16|Pre-Art Clients Alive and Care at end of 12 months
AFF683F8-2519-4375-8757-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|78f60789-4232-48a2-8068-38404826b034|Chart: Median time to ART Start among pregnant women at ART start by AgeGroup
A78EACC4-A74A-4353-87B6-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|e2286829-92e4-4d5d-a8f1-4f803f3993d9|Chart: Active / In-active Patients by Start ART Year
A6052ED6-B8F2-4165-8802-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|ee70258f-31f3-4ea4-bb5f-db53796c801c|Table: Outcomes by County
45ED11C3-D784-41BA-882B-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|4d42dc65-7bef-40fd-a090-29d208015135|Table: 12mARTOutcomes By AgeGroup 
583A5E88-29D5-4700-883B-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|210105e6-8890-4b35-939e-c7068296a346|Dash_Chart: Dr. Wamicwe
B47BFB60-F01D-4EE4-8857-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|f192a387-ac71-4744-aff5-d01e798a39c8|_Chart: 6 month Pre-ART outcomes
850D22A1-D625-4D8B-88A7-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|0fc7c64c-474f-486e-9558-62011e1844b9|Chart: Cohort 12 month ART Outcomes for Pregnant Women at ART Start by Agroup
C906E1B4-1ED1-4207-88CA-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|82f4d5d9-d1ac-4a84-8354-346505dc3695|Dashboard: Median Time to Care and Time to ART Start
BE8FF063-0D54-4D9C-88DE-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|74db7e27-0e5c-47e2-bf9c-5e70e1f8cb33|Stripe: All Adults (15 and Above) stripe
7E0AF37E-6284-4593-8909-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|ce988304-807b-40cb-9a3e-b2ecbb2c8daf|Chart: Median Time to Care
F02E2866-4FF1-4573-891E-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|80d2131a-6c72-483f-8669-9e8e6856bd0d|Cohort_Dashboard: Pre-ART Cohort
402C9466-0235-4B20-8938-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|d73de26f-7a19-449d-8577-c55878370f10|Chart: 12m,24m,36m,48m,60m retention by CD4 at ART Start
511F9E9E-4262-4A97-8945-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|06a7ae03-7c13-4a30-a0b9-306ae02db5d4|Table Enrollment CD4 distribution by Age at enrollment (Adolescents vs Adults)
44B90B26-C36F-4E2A-8950-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|2af06d0f-245c-49a3-8d57-bf557d336e38|Chart: Cohort 12 month ART Outcomes by Baseline CD4
F379658E-F977-45CB-8A48-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|1849f985-5bcf-4b3d-b85d-20883f892533|Chart: Median CD4 at ART Start over time
A1F23AE0-25D9-49E8-8AE2-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|6def6484-6ab4-4e39-a534-cb69cef24a40|Chart: Age at Enrollment (0-65yr)
605DCA02-A0F4-4B8C-8B03-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|9306308b-ad63-4f7f-bc90-2f609e5788be|Table: ART Cohort Current Regimen Line
D52BEA41-147C-499C-8B42-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|5e2ba0b2-47b7-4460-9ecf-6f29180fa1ba|Chart: Has CD4 at ART Start
2ABF29DC-B2D3-4F4D-8B8E-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|8b718608-f439-4c58-9c68-df1a7131e9a5|Chart: 12m,24m,36m,48m,60m retention by Year of ART Start and Gender
01AF53B5-E753-4D06-8B9B-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|2b927729-ccec-4bbe-bb1b-4d777574ea46|Table: Valid / Invalid Time To Care Distribution 
EABFF368-2843-4082-8BA0-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|40014124-e082-44a0-b42d-685490599a7e|Chart: Retention by Facility
5E766658-DA57-4196-8BCF-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|b2ac7912-c570-46de-89d2-ab9aeb82a59a|Chart:  Distribution of Initial CD4 count  by enryr of adult clients: National
C6FEDBA6-F90E-46CF-8C87-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|e4742735-57e6-4cab-836f-df257655ee11|Stripe: Number of sites with clean data
2765C109-EA32-4FDC-8D03-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|8c346f9e-b0ec-41a3-8bac-591eda153c45|Chart: Viral Load Uptake among Pregnant Women
04C3D9D2-1253-48E2-8D1F-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|96dbbd90-83ab-4d70-a3ec-05323d1a61a8|Table: CD4 Distribution for all by gender
EC9F5BCC-AD31-457D-8D4C-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|ba793604-2866-4c01-a39c-204efb88df66|Sheet 165
E7525240-E70A-4262-8ED0-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|c104cb55-4e3f-4f97-a06b-131ea9b87b0c|Chart: 12m,24m,36m,48m,60m retention pregnant women at ART start by Age Group by Project
BA1C956A-466E-4A6A-8F1C-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|5b53434f-1d43-45b5-a458-585cf0b95e43|chart: Retention by County
8848532F-722B-445B-8F99-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|0b250bd3-cc6e-4b85-b3ec-dc5eea992f60|Chart: Distribution of Pregnant women by Age Group at ART start
D32409D7-9885-4286-9017-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|5564956a-06d0-46dd-81fa-241a5f0a0b72|Chart: Table Median Time to ART Start
9179B5B5-61C4-417C-901F-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|3421e9ff-6cbf-410d-9436-3cd4844c92b3|Sheet 193
B37310B6-6C6D-401B-90CF-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|d3ac5292-1bb2-4de9-a521-64cebf0e3c21|Chart: Time To Care (P50,P75,P95 by Age)
453BADDE-B11B-4846-90FD-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|56f53299-c528-400b-a35e-85f7dc854035|Chart: ART Cohort 12m retention by Age Group
AF977E8E-1CC9-4BA5-916D-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|a75b7413-2f0c-49b4-9165-86d20b78e288|Chart: Viral Suppression among ART Patients
D5877AC9-2D33-4047-91AE-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|3cfd957c-d867-4d2c-9b7e-6501e347f544|Chart: 12 month ART Outcomes for Pregnant Women at ART Start
030F26F2-5876-4BE2-91BE-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|d82ee68f-f9ce-4abf-ae78-2d39038216db|Time To Care
FDC005E3-169B-491C-91E3-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|6e42043e-a7db-4193-bf1b-b24d36f18360|Chart: Retention pregnant women at ART start by BaselineCD4
92B07FA4-D1C8-4066-92C7-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|4f11e274-ff17-415a-a177-64812425f210|Chart: ART cohort age distribution
3F55FFE7-CD01-4E84-92E5-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|f0ee40e1-1287-4709-b239-8e0308fe805f|Chart: Number of clients eligible for viral load who have recieved viral load tests by year
22E0DBE2-F4DA-42B7-92F0-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|e63fdb57-5227-4a1f-9b1f-1d11eb91e316|_12MPreART_Outcomes Chart
F5F54014-E5B8-42B1-930D-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|593d7bdf-928a-4892-8594-18e2b0b68441|Table:  Distribution of Initial CD4 count  by enryr of adult clients: National
7E802C18-813F-485A-935E-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|94b399bd-9da7-4872-9593-c514eef2510b|Chart: Median CD4 at enrolment by year of enrolment and sex of adult clients: National
48B3B05F-0D73-4EC8-93EA-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|e67da5c8-8e81-4a37-ac21-b011b2d45a9c|Chart: Number of days to ART start Paeds vs Adults
9C5ABEED-C031-4929-93FC-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|5183bf99-bb41-4874-a02f-24c6b4eab195|Chart: Viral Load Uptake among Active Clients
253ABD11-12A3-4A22-943C-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|51effd29-b8df-4fae-b2f3-aa98c4df8cb3|Table: Viral Load Uptake
F656E369-3E92-4788-948B-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|01cc3b10-61f0-4aa3-a9a6-eb35675d6107|Table: Enrollment Numbers by Age
636D17E4-AA85-49EB-94C4-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|5e642982-ee73-4d02-8c14-8dd9a05c7784|Table: Age at Enrollment (0-65yr)
D057F139-C561-4B2E-94C7-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|890e4d2a-ab48-48a7-9dd1-b6be35c2b051|Stripe: Pre-ART Under 5 Years
5F9ED145-2FC7-4B91-9524-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|dadf18dc-22e2-4af9-81a0-a4f7cff4e824|Chart Median time (days) to ART start by year of enrollment. (Children vs Adults)
4F5C2E40-F922-4862-958C-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|1baa62a4-f6c2-46b3-bc4d-a2e3341d0f7c|Stripe: ALL ART Patients
9688B0C8-500B-4614-95EC-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|784a3bd3-fd15-44b8-9b01-b66e188828ba|_6MPreARTOutcomes
E26295B6-821F-4D4D-9603-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|8f0eecf5-6da4-49fa-9477-48a63448d0fd|Table: Number Of Patients By Age Group
7F3E4A29-3E67-4262-965F-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|6c27a144-b15f-4636-a8cb-a44ab1157c0a|***6 month ART Outcomes for Pregnant Women at ART Start
DE7BAF91-8856-4E52-96AA-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|60ab69f8-5701-4483-b40f-af3e7aa64f32|Sheet 174
0CAD323A-E351-4C95-96E8-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|7d2ce6e1-8897-4e96-9c4b-81f93476087c|Chart: 12m,24m,36m,48m,60m retention Age Group
24E61F12-17DD-4AE5-96EF-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|f04958fe-b94c-492f-a804-bc1730313261|Chart: ART Cohort Population
1768746C-0811-400C-970F-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|0da957e8-7624-44d0-a239-ff14a61b162d|Chart: Client Age and Sex distribution
18C0B85B-B04B-4F66-971A-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|514817d1-3454-476f-aadd-f471f3f6e84b|Chart: Proportion of Patients by Age group
FB831D51-94EB-4412-9741-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|31b38ec9-1c46-4879-b217-42bcc152503a|(Proportion) Time to linkage  (Late vs Early linkage) 
074B834D-8D96-45CD-9771-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|6b042ef7-fd2e-4798-b02e-482689bcd914|Chart: ART cohort sex proportions
37AC8E06-5492-44CB-9778-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|ea88fece-64a2-48a5-9448-3c747ed6b06a|_Chart: Median Time to ART Start by gender
291C3D4D-7157-44B1-979F-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|9a11fe44-2395-4a93-9405-286d30860a95|Chart: Proportion Started on ART Patients Peads vs Adults
1E4D2901-3BBD-4BB5-979F-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|6360d0a9-9089-44e1-bc0d-ecb07f8584f9|chart: Retention by Sub County
84C27418-3672-4135-97C8-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|1f712957-88c8-4d11-8cb6-cc5ab36171ac|Kenya map
589024AA-9225-48C0-97CB-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|56fe2bf4-c244-406d-b95e-f24f78a1aa1e|Chart: 12 month Status Table
124F9E08-4592-4E55-980D-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|46d84ef3-eb12-4fde-bfe3-343212b656f7|Chart: Median by Year of Enrollment
54546344-BA3C-4619-9858-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|9e15013d-d02b-42de-937d-5843dc5845f8|Chart: Median CD4 at Enrollment over time
C15AE256-CBFC-4D99-986C-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|be1c6e39-7c52-4b21-9170-dae7cac87fcc|**Median time(days) to ART Start among pregnant women by year 
156D1BDE-9664-4C9B-986C-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|14c5980b-3181-4ef1-98be-0195a8b27f3b|Chart: CD4 Count By Sex
424556C8-6C97-41BE-9872-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|c621de53-9a60-40e7-83a1-751362caa7e1|Chart median time (days) to ART start by year of enrollment
173BDA0E-3F91-4A77-98A6-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|90ab87ed-bbdb-49cd-a138-848bf02ee338|Chart: Number of Patient Records
71A3D514-C790-4489-98AA-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|7edb6a86-735e-42a8-8cef-e63152938480|Sheet 191
66957776-55E3-47AA-9915-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|4447f659-85a7-4a5f-8f41-90c70fa22c3d|Table: Number of Patients with Baseline CD4
35CE39F5-5F0C-4C1C-991D-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|3ad92aab-9dc6-4c33-888e-aaf53c02c410|Chart: Marital Status
D7931CCC-5E7B-4ED4-99A1-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|c87aa501-7d37-42f3-90a3-2b24ed84469b|Chart: Client Sex(proportions)
3B7FECA4-56C2-4570-9A38-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|63a602b1-f503-4fe5-a36b-eec5e9c9003a|Chart: Yearly proportion started on ART Patients (Peads vs Adults)
4072689D-8908-4C5E-9AA1-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|36eab196-1034-4f8f-9e7d-b4694e4519d1|Table: Time (days) to ART start by age group
0D3341AE-AA3A-4DD4-9B95-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|cc7c4997-603c-425d-9ad8-82e35d8edf56|Chart: Proportion of  ART Patients Started on ART By Age Group and Gender
A9584920-7EB3-42DD-9C19-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|d31e285f-6e9e-4511-ae62-deef1fe46418|Chart: Proportion of ART Patients by Age group at ART Initiation
35363FE4-0B90-488A-9C83-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|22332e1b-d06a-4447-a669-13a75f78349d|Img: Woman
A9789B81-68F7-4FA6-9C95-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|737ee125-5cc5-44e4-b856-2ecf5cd5d5fd|Table: Number of  ART Patients Started on ART By Age Group and Gender
C922812E-3AB1-4004-9CA3-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|21e361f3-f30b-48e1-a6e8-e418d7b0528a|***12m,24m,36m,48m,60m retention Of Prgenant Women at ART Start by Regimen Line At Initiation
B389535A-DB7D-4A6B-9D3E-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|927c1dec-130c-4bf4-9863-28e7826dfcea|Live Dashboard: KenyaHMIS 12 Months status
A4DDBABE-D5E0-4A36-9D5C-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|e61d8d19-c2ae-4389-b9e4-d23605632342|Chart: Cohort 12m retention by CD4 at ART Start
801B9BC2-4E15-402D-9D82-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|774a67b3-4309-4b68-9538-bd78cb6e237d|Dashboard: Proportion of Patients
2DC8E891-D2B6-4B19-9E59-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|9485c066-74db-4378-b6cc-39c55239187b|Table: Baseline CD4 by Age Group for Pregnant Women who died within 12 months
FE9E4549-3F45-46E2-9EF2-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|c531c2d3-acf6-46e4-a222-c577dc412e50|Stripe: ART Total Population Stripe
1A84FF6E-B766-40CD-9FC7-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|a926bb6f-1d46-46e9-8856-907b33228663|Chart: Proportion of  ART Patients Peads vs Adults
25D1902A-6FF3-4126-9FD9-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|068f85fe-d24f-4bb7-b425-976f5d251af4|Chart: (line) Time To Care (P50,P75,P95 by  Patient Source)
EE89D9A3-F6A2-4E78-A0A2-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|676d3b60-4bf8-4bf0-8b07-bb8c34314be4|Chart: 2015 Cohort 6 month ART Outcomes for Pregnant Women at ART Start by Agroup
0325B01B-E27B-4B00-A112-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|6a05bbd6-22b0-4cee-8588-fe3972f56edb|Table Number of Facilities
46E1BBDA-100E-405B-A182-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|de10f325-ac4c-4359-aa0f-e14aadb63f60|Table: Marital Status
22C25E2E-8A57-479B-A1F8-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|9e412a02-de08-406b-9a0d-404f437c45b0|Stripe: All Adult Females (15 and Over)
6F24304A-EF7F-4F21-A215-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|f98bab43-ee6d-47de-9764-d78dadee3b77|Table: Median CD4 count at enrolment by age / sex
F8C4F378-0700-4FE9-A218-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|43d571eb-4ad9-4df1-8cb9-3daad561b35b|Pie Chart: ART Cohort Age Distribution
B563A1BE-3C79-4518-A21D-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|e6a081da-f271-43e7-b839-530fc4c6a6b7|Chart: Emr by Type of Facility
AF7E4A57-F0FB-4AD3-A24A-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|7331ca0c-7b56-454b-994e-1c43c5ae5741|General_Dashboard: Patient Distribution
CAEDC371-8E25-4960-A281-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|cfdc65d1-cbb6-44d4-bc20-40a289e5c69a|Table: Proportion of Patients by Agegroup
5D5D51AD-82B7-40F9-A2BB-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|56d5d2ec-a57c-4548-9361-54f0db484f14|Chart: Proportion of Patients with CD4 at Enrollment (Overall)
1EB9A51D-5200-4F9E-A2D2-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|2ba65b5e-e0e9-4b22-9de3-848fb9c4f70d|Table: Number of Pregnant Women who died with 12 months by county
179038B8-F5F9-4C48-A35D-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|02856878-e32d-4523-bf2f-47311d4770a5|Stripe: All Children (5-14) stripe
F70DBDC4-18D4-47EF-A3E4-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|999db1fb-6ae4-441e-b97b-81dfd45076d2|Chart: 12m retention Of Prgenant Women at ART Start by Age group 
269B8D15-B9A2-4161-A499-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|f054205b-13e7-449b-b57f-daae98b1e65e|_Chart: Overall Time To ART
E5181183-888C-4492-A4D2-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|5b63544e-5570-4895-b7fa-8aa5ad8259c1|Chart: Viral suppression among pregnat women
8E4A5B38-DF82-476C-A4D6-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|b36651c0-b9ac-4372-bdf3-0612acbfcd99|Table: Number of  ART Patients Peads vs Adults
9B2A9A64-78D4-41DA-A50D-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|3e540fc3-b949-40c6-815a-a665d5998c50|Chart: 12m,24m,36m,48m,60m retention pregnant women at ART start by Age Group By County
BCFE0F4F-66DA-425A-A50E-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|c26d504c-02f8-4777-88f2-f083e2dda18d|Stripe:  ART Children 0-14 Stripe
B85B9BFC-9BC6-4104-A519-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|7ed0c926-3d08-452e-9e10-5457733faaad|Chart: Time To Care (P50,P75,P90 children 0-14)
EE2A7F4F-637E-42F2-A6B5-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|563f684c-1a75-4dfe-95bf-fc2a0e4df31d|Sheet 194: Retention Varied
182C5A6C-15C4-4ACE-A706-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|6267fbd0-1d8b-433a-aeb8-90786d9c8546|Chart: Viral Suppression among Pregnant Women on ART
12E425F7-DC6E-4C36-A737-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|e097dfe6-bb96-4297-a8f2-ca6336e79528|Img: Children
ECE317D4-165C-4F91-A737-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|374ad146-6273-451c-806d-0e7cf86bac96|Sheet 183
C0974FBA-96D4-414A-A753-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|2b87fb23-4563-453d-9969-dea303128e7c|chart: Retention by province (KeHMIS II)
131CD195-5318-4CBA-A79A-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|3a109c4c-3484-4877-9af1-c8615d1e7846|Chart: EMRs Uploading data by County
88D3AA8A-2C63-40B2-A826-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|08f91740-e5ab-4bf1-b2e0-6e92f21487b3|Sheet 179
C0589C0A-08DD-4710-A94A-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|71521d77-e61c-44cd-b36b-e083caa849c8|Sheet 164
8B9BAE84-1785-45E7-A9CF-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|2f15d60a-072e-4422-bf7d-c0ec58eb9750|Table: CD4 Count by Sex
0322FFFE-F47D-4499-AA2E-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|19fd254a-18f3-423d-be54-d52c4988dde3|Stripe: ART Children (5-14) stripe
A6B91C6F-F282-45FB-AA4B-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|b57436c2-854b-4e42-85cf-c55265b62790|Stripe: ART Under 5
278B1A53-0E4B-4869-AA6F-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|9a8d9ac9-a087-4d0e-9ae3-64cd0087e344|***Last ART Regimen distribution among pregnant women at ART start
BBF56E9B-344B-4B37-AAAA-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|a4d123a5-2d72-4e49-854d-87fd1d446b2b|Chart: Time (days) to ART start by age group
AC4C3F28-7718-43CA-AAB7-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|70e8d1e0-00aa-4a6e-90c2-cefe7f465376|Chart: Average Std Dev Median Age at Enrollment
0E07E171-4773-466C-AD67-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|9cbb24a2-7135-434e-a036-e483ad52e021|_Chart: TimeTo ART Start groups
7E0B4353-209A-45EC-AD86-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|e4d2d9e4-0b9b-487b-b64f-7640e6469586|Chart: Median Time to Art Start
665C7AF1-8813-4B08-AE04-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|b66dcf65-01a0-4f85-8f41-d5074fe570ba|Live Dashboard: Distribution of Patients in DWH
5574D2EF-3CD1-425D-AEE8-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|d292c89e-174c-473d-a050-855622240f52|Chart: Cohort 12 month ART Outcomes for Pregnant Women at ART Start
7EBF49AA-E6FA-4CB7-AF03-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|3a08fd7b-7ccc-4c46-9cad-42318b5bbcd3|_Distribution of Clients enrolled in 2014
D0259BF6-44C4-4C08-AF0D-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|c19fcbd4-0b82-4b29-aceb-5872a3b2ce3e|Chart: (Marks)Time To Care (P50,P75,P95 by  Patient Source)
FCF523B4-015C-4FC7-AF33-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|9fd63f67-4b3a-4c21-ae8a-22cbc6ef94c4|(Numbers)Time to linkage  (Late vs Early linkage) 
2DC66165-50B6-4755-AF61-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|609d94b9-ed60-474d-aba7-6f6d3f52bba9|Stripe: Pregnant ART Adults (15 and Above)
31655410-A51E-4384-AFC4-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|962599a5-0c1c-4cfd-8cd8-f8faf6f0f3b8|Chart: 12 month status
77BED200-358E-4A73-AFCF-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|5b41e483-cad3-4ad9-a42b-e29b0624ea73|Table: Median CD4 at enrolment by year of enrolment and sex of adult clients: National
D3D37807-DA65-45FB-AFF3-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|043643c3-e701-4c3c-a26d-502854260b8c|Stripe: Number of sites intially uploaded
E24F55C8-2CB4-47D4-B005-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|531f9457-9af6-4f13-8a83-f2bd4e165c91|Stripe: ART Adolescents
75E6C637-CBB2-48FD-B011-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|a9006617-7725-4546-9854-2c0511a198cf|Chart: Time To Care (P50,P75,P95 by Sex)
4A501CDD-CD23-4988-B031-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|b9414127-b5cf-48d9-a458-f574202ca080|Chart: Median CD4 count at enrolment by age / sex
52C8CA1B-47AC-420A-B042-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|adce011b-b00c-49a7-80dd-68d2f0c5c2e4|Stripe: Pre-ART Children (5-14) stripe
A83BD7A7-CA17-4757-B07C-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|e8ab9b3e-baac-49f3-8706-aac13a9d3b31|***6month ART Outcomes among pregnant
95A2D654-2609-454A-B0C8-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|1233126a-5578-4721-8a06-cc4535e207b2|Chart: Cohort 12 months ART Outcomes
68536C50-1905-4E2A-B278-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|b1cb0de7-3b7b-4a66-80b3-5014528e45b7|Chart: Cohort Pregnant Women by Marital Status
2E68812D-8C57-4CC6-B2C8-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|db4ab079-9e15-4af2-84cf-6e549b9ef703|Stripe: Pre-ART Adolescents stripe
EF2FBCB0-2CEA-4D11-B2CB-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|99ffbd8b-d72b-45c8-bbdc-ab5a52571457|Table:Age at Enrollment (14,15+)
D6A0D42F-9064-4786-B2CF-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|5416d3b9-4170-4afb-92e4-b25d33893117|Number Of Patients
AC608811-597F-464C-B2DF-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|eb65f5e6-94cb-403b-9377-9c717b3306c3|Img: Man
71484381-5473-40FA-B352-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|a7dde063-fd15-4385-87bc-60111925ae47|General_Dashboard: Active ART Clients
FFF03B57-0E6A-4EC9-B356-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|f5f40c4f-3daf-4828-b339-b2f07309bd48|General_Dashboard: ART Clients
EC364277-19F4-4EA1-B389-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|2f4fa36c-17f0-4bf3-94fc-d55f171fe1b9|Img: Adults
028F62A6-74FD-49F4-B39B-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|bfc09bd4-5c57-46dc-b3f7-2d39cf0a3b93|Cohort_Dashboard: ART Cohort
CAB6A15D-94CB-4F49-B3E7-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|83ab1a2b-3cd0-4e91-b035-97d0c3f459ab|Stripe: Pre-ART Children 0-14 Stripe
8152306D-29F6-46BA-B43A-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|df8828bf-38c2-4d22-9dea-bfce9d529d79|Stripe: Pregnant ART Adolescents
8DE20786-127D-44F5-B488-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|99808ce4-c64d-49fa-b496-b585845d29cf|Sheet 163
0538A591-76DA-41C1-B4A0-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|45aead3a-f8a3-4b30-ac60-735ae4e21bfe|Chart 2.2.5: Paeds initial CD4 % (0-4) 
576D9DA7-F7E9-4C80-B50F-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|138a3c09-8391-40e3-a59b-71cce745776c|Stripe: Total Population
80672932-CB93-4E93-B51F-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|d2c13976-99a1-4be7-8943-3238ec493f93|Chart: CD4 Distribution for all by Gender
D73281C8-0606-4454-B60E-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|534b43bc-f375-4ed1-8bbd-d0f44f3cb259|Table 2.2.4. Availability of paediatric Initial CD4 count  stratified by age: National
A3BAA454-7AF3-456A-B6E3-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|b6955fa1-5c75-4cf9-9a7d-7569810775cf|Chart: Pre-ART cohort age distribution
13645682-0F60-41AC-B6E4-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|afa6b7bc-0e11-4954-b8dc-2058d81ff642|Chart: Proportion of Clients by Age and Gender at enrollment
98280BFA-6B2B-41E5-B6EB-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|23fc8aec-2fc9-4534-ae2d-b98ce9f4fcc2|Stripe: ART Net Cohort
9C340A03-BB99-4A84-B722-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|7f429cb5-88d7-47f1-9c09-c0f46523c6fa|Live Dashboard: Site Monitoring
A71444C4-E6B1-4FB7-B723-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|75298fe0-e550-420d-a648-4600e1e59745|Chart: Proportion of Patients with Baseline CD4 By Age Group
8FCDBA7D-07B7-4DC2-B7CA-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|a44827d8-8d5d-4bed-bfd5-8254f8a5d86b|Chart: Median Time to ART Start
7CDE7CE5-C58C-4687-B7EE-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|98f5acce-f2da-48a4-8e0b-ddf64f27ee87|Chart Last Database Excounter
D3482B01-6B85-45C9-B868-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|4fc87055-ff63-4f07-bd4e-3cbafaec6c14|Table: EMRs Reporting By County
175E05C2-3FC6-43B0-B86B-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|314a6229-c495-49a3-86ae-7e227c366ea1|Sheet 182
572A5321-647A-4FFE-B8B9-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|ff67a5cb-0162-4462-b693-ad8d4a834306|Table: Age at Enrollment (9,19,20+)
C5FA4AED-EF41-43F5-B8F2-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|8f42e01c-963c-4098-9366-78a92c4fbf40|Img: Population
0B8FBAF7-EE7D-4944-B8FA-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|c8980209-df64-46cc-bc75-aeafc6716f20|Stripe: ART Adult Females (15+)
02211F00-9EC9-44C6-B8FB-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|9fac204b-a0be-46ff-9042-96697049f701|Table 2.2.5: Paeds initial CD4 % (0-4) 
912FC78D-FE95-48C4-B900-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|5824ace2-2026-4d37-93ca-d36947bdc112|Stripe: ART Adults (15 and Above)
D4CC0C65-5D4F-4546-B92A-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|19670382-279c-4e09-811b-49aa19f52588|Proportion of Patients with baseline CD4 at initiation (ART)
0FFDD7DC-E9C0-47D2-B969-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|a5ad8504-f049-47b0-b2f0-45f4a62b133d|Chart: Pre-Art Cohort distribution Age and Sex(proportions)
A94E1ACB-B3F6-4786-B97C-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|6e8f69ea-4029-4921-a774-973d0ed05919|Stripe: All Adults Men (15 and Over) Stripe
DF98A68F-B71F-45A5-BA20-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|aff640b2-1c7d-4fc5-9df9-d6c7c9a6e866|Sheet 186
C72BE4C2-974B-4BD4-BB34-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|18ab7b8e-fd12-4e3b-968f-9ad64878fdce|Chart: Proportion of patient records by EMR
F9E86DB0-E319-44C1-BBCB-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|a560a246-da49-4358-a5ab-08b98c7375bc|Chart: Number of Started on ART Patients Peads vs Adults
1996506B-E8F9-4CCB-BBFB-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|04938ed1-28b6-45f0-b9c2-37a39170ab8d|Old_HIS Report Dashboard
F8CB619B-992A-4993-BCBB-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|994640e3-a3cf-4ff5-a441-4a65aaadcf45|_Chart: CD4 Distribution for all by Gender
AC733E30-275F-47A3-BD3A-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|8d936d12-9187-4752-866e-e8288198116e|Chart: Table Median time to care
E431D8F1-3327-421A-BDA9-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|027f1a2d-9f5d-4687-87ef-011695580bc1|Table: Number of  ART Patients By Age Group and Gender
C37ED44D-6A03-4C10-BDAF-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|9280e1ce-ac86-45e6-982e-deb65959aa35|Stripe: Pre-ART Total Population
67D5F5D3-22DD-4D18-BDEE-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|ef9bbc6a-e4ea-4e20-bf1b-3fcff0620d43|Chart: ART Care Continuum
34B1FAA5-A3F9-4689-BE95-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|6e3cdd98-fac0-40f4-aebc-7518b60f49b2|***Initial ART Regimen distribution among pregnant women at ART start
A42DA745-CA61-4172-BEEA-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|2f4c052d-2dde-41d4-bb26-962fbfcde015|Stripe: All Children 0-14 Stripe
09CFE4C3-9A30-4A50-BEEB-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|e01af849-b0e1-4f2c-a153-d670a801b303|Live Dashboard: ART Cohort
8F24AE72-ADB1-44DB-BF18-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|6039294d-7c4b-4979-9f80-5cb476c5d159|Stripe: All Adolescents stripe
3D6CE381-41EA-40B9-BF29-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|d3b299e8-1a21-434f-baf5-52509e730753|Chart: 12m,24m,36m,48m,60m retention pregnant women at ART start by Age Group
FBC5CDE8-6FD4-4713-BFC6-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|a3871e83-dd1f-42fe-a421-0622a3ca2446|Chart: Retention by ART Start Year by Project
285079E9-5745-4E00-BFE4-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|1af32c50-2841-4b69-bd97-3a7b9a9c4207|Chart: Active Clients Age and Sex Distribution
9BE5E999-58BD-455D-BFFE-A7A1012EFD5A|27e96b74-e2a6-4005-8aac-c9ea9d9d0de5|16B1157D-2ECC-41B0-A7BD-A7A1012EFABD|07a25870-d80a-47a2-b9da-ed8b9a6a0d1b|Number of Patients by Age at enrollment by Year 2004 - 2014